nach oben

Reactions Weekly

Erschienen in:

01.11.2023 | Case report

Antineoplastics

Death, secondary neoplasm and lack of efficacy: 3 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

* death
* life-threatening
* hospitalisation
* disability
* congenital anomaly
* other medically important event

…

Mitrovic Z, et al. Dose-adjusted EPOCH and rituximab (DA-EPOCH-R) in older patients with high-risk aggressive diffuse large B-cell lymphoma: A real-life multicenter study by the Croatian Cooperative Group for Hematologic diseases (KroHem). European Journal of Haematology 110: 725-731, No. 6, Jun 2023. Available from: URL: https://onlinelibrary.wiley.com/doi/10.1111/ejh.13957

Titel: Antineoplastics
Death, secondary neoplasm and lack of efficacy: 3 case reports
Publikationsdatum: 01.11.2023
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-023-49402-0

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Antineoplastics

Death, secondary neoplasm and lack of efficacy: 3 case reports

Excerpt

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2023

Afatinib/strontium-89

Sabril (vigabatrin) 500mg tablets containing trace amounts of tiapride released on Canadian market

Multiple drugs

Antineoplastics

Elexacaftor/ivacaftor/tezacaftor/ivacaftor

Amiodarone/mexiletine/sotalol